Jazz Pharmaceuticals, Inc.
NEWS
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
This approval was based on the Phase III withdrawal study that showed clinically meaningful differences vs. placebo in change to the primary endpoint, Epworth Sleepiness Scale score.
Although August is a fairly busy month for PDUFA dates, there were only two on the U.S. FDA’s calendar for this week, and one of those has already been reported. Here’s a look.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
FDA greenlit Jazz Rylaze for use as a component of a chemotherapy regimen for the treatment of ALL or lymphoblastic lymphoma in pediatric and adult patients.
Life sciences news sometimes flies under the radar. So here’s a look at a few stories you may have missed.
Jazz Pharmaceuticals will beef up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.
JOBS
IN THE PRESS